For example, CD133, a stem cell marker known to be hyperactivated in cancer stem cells [110], was found to be exclusively expressed in MYCN-amplified neuroblastoma cell lines, where it promotes the survival and proliferation of the tumour cells [107], and was shown to asymmetrically co-segregate with Numb during ACD in glioma stem cells [111]. Here, MYCN is linked to neuroblastoma.